pmc logo image
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Journal List > Br J Cancer > v.67(1); Jan 1993

Formats:
Br J Cancer. 1993 January; 67(1): 10–14.
PMCID: PMC1968239
Copyright notice
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.
R. A. Nagourney, S. S. Evans, J. C. Messenger, Y. Z. Su, and L. M. Weisenthal
Memorial Cancer Institute, Long Beach, California 90806.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside. The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class. The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may help to elucidate drug activities and mechanisms of action.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (909K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 10
10
icon of scanned page 11
11
icon of scanned page 12
12
icon of scanned page 13
13
icon of scanned page 14
14
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res. 1989 Sep 15;49(18):4972–4978. [PubMed]
  • Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985 Jan;101(1):4–15. [PubMed]
  • Berger NA, Sikorski GW, Petzold SJ, Kurohara KK. Association of poly(adenosine diphosphoribose) synthesis with DNA damage and repair in normal human lymphocytes. J Clin Invest. 1979 Jun;63(6):1164–1171. [PubMed]
  • Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res. 1986;10(4):445–449. [PubMed]
  • Bosanquet AG. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents. Cancer Chemother Pharmacol. 1985;14(2):83–95. [PubMed]
  • Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet. 1991 Mar 23;337(8743):711–714. [PubMed]
  • Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990 Nov;86(5):1480–1488. [PubMed]
  • Carrera CJ, Yamanaka H, Piro LD, Lotz M, Carson DA. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv Exp Med Biol. 1989;253B:219–225. [PubMed]
  • Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Natl Acad Sci U S A. 1984 Apr;81(7):2232–2236. [PubMed]
  • Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW, Jr, Robins RK, Montgomery JA. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6865–6869. [PubMed]
  • Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983 Oct;62(4):737–743. [PubMed]
  • Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990 Jan 17;82(2):117–124. [PubMed]
  • Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989 Dec 15;49(24 Pt 1):6923–6928. [PubMed]
  • Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem. 1990 Mar 5;265(7):4033–4040. [PubMed]
  • Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992 Mar;10(3):371–377. [PubMed]
  • Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus. 1990;33:295–298. [PubMed]
  • Pemble LB, Lihou MG, Blakley RL, Jamieson GP, Smith PJ. Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells. Cancer Chemother Pharmacol. 1987;20(2):155–161. [PubMed]
  • Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988 Sep;72(3):1069–1073. [PubMed]
  • Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990 Apr 19;322(16):1117–1121. [PubMed]
  • Santana VM, Mirro J, Jr, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol. 1991 Mar;9(3):416–422. [PubMed]
  • Santana VM, Mirro J, Jr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar;10(3):364–370. [PubMed]
  • Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985 Feb;75(2):377–383. [PubMed]
  • Smulson ME, Schein P, Mullins DW, Jr, Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 1977 Sep;37(9):3006–3012. [PubMed]
  • Tanabe K, Hiraoka W, Kuwabara M, Sato F, Matsuda A, Ueda T. Induction of DNA double-strand breaks in Chinese hamster V79 cells by 2-chlorodeoxyadenosine. Chem Biol Interact. 1989;71(2-3):167–175. [PubMed]
  • Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol. 1989 Nov;43(5):374–384. [PubMed]
  • Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983 Feb;43(2):749–757. [PubMed]
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK